KURA News and Press, Kura Oncology Inc. From 02/24/21

– Preliminary clinical data for menin inhibitor KO-539 highlighted by single-agent activity in relapsed/refractory AML, including patients with NPM1 mutations – – KO-539 continues to demonstrate a wide therapeutic window in dose escalation; protocol amendment to inc...

SAN DIEGO, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that its investigational drug, tipifarnib, has been granted Brea...

SAN DIEGO, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive off...

SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2020 financial ...

The following slide deck was published by Kura Oncology, Inc. in conjunction with this event. For further details see: Kura Oncology (KURA) Presents At 39th Annual J.P. Morgan Healthcare Conference - Slideshow

Illumina ([[ILMN]] -1.7%) announces a portfolio of strategic  partnerships that aim to expand the reach of its powerhouse comprehensive genomic profiling family of products, TruSight™ Oncology.Myriad Genetics ([[MYGN]] +5.5%) to create a kit-based version of the myC...

In a regulatory filing, Kura Oncology (KURA) announces that on January 04, it entered into a collaboration agreement, with Illumina (ILMN) for a companion diagnostic test for use with the company’s lead product candidate, tipifarnib.The agreement tided to a project schedule w...

SAN DIEGO, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation at the H.C. Wainwright BioConnect 2021 Confere...

Kura Oncology looks an attractive opportunity in the Precision Medicine / Targeted Therapies sector. Since its IPO in 2015, the company's shares have gained 383%, and in the past year, 145%. There are two candidates - Tipifarnib, a farnesyl transferase inhibitor indicated for HRAS...

SAN DIEGO, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the JMP Securities Hematology Summit. Troy ...